Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Nervous Tissue: Myelin01:25

Nervous Tissue: Myelin

The myelin sheath is a multilayered lipid and protein covering that insulates the axon of a neuron, enhancing the speed of nerve impulse conduction. Axons without this sheath are referred to as unmyelinated. Two types of neuroglia, Schwann cells in the peripheral nervous system (PNS) and oligodendrocytes in the central nervous system (CNS) are responsible for producing myelin sheaths.
Schwann cells begin to form myelin sheaths around axons during fetal development. They wrap around a small...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy of cognitive rehabilitation in cognition and brain networks: A randomised clinical trial in patients with multiple sclerosis.

NeuroImage. Clinical·2025
Same author

Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom.

Journal of medical economics·2023
Same author

Dystonic head tremor secondary to neurocysticercosis.

Neurologia·2023
Same author

Epilepsy and pregnancy. Factors associated with epileptic seizures during pregnancy.

Neurologia·2022
Same author

Gadolinium-enhanced brain lesions in multiple sclerosis relapse.

Neurologia·2022
Same author

Diagnostic confusion of demyelinating lesions and incidental diagnosis of a new pathogenic mutation of the FLNA gene.

Neurologia·2022

Related Experiment Video

Updated: Jun 23, 2026

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
04:55

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

Myelin peptides in multiple sclerosis.

L Grau-López1, D Raïch, C Ramo-Tello

  • 1Department of Neurosciences, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.

Autoimmunity Reviews
|April 28, 2009
PubMed
Summary

Identifying specific peptides in multiple sclerosis (MS) is crucial for developing targeted therapies. Research shows limited differences in T cell reactivity to these epitopes between MS patients and controls, impacting diagnostic and therapeutic strategies.

More Related Videos

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies
10:47

Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies

Published on: October 27, 2016

Related Experiment Videos

Last Updated: Jun 23, 2026

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice
04:55

A Stably Established Two-Point Injection of Lysophosphatidylcholine-Induced Focal Demyelination Model in Mice

Published on: May 11, 2022

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin
08:57

Experimental Demyelination and Remyelination of Murine Spinal Cord by Focal Injection of Lysolecithin

Published on: March 26, 2015

Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies
10:47

Simple and Efficient Production and Purification of Mouse Myelin Oligodendrocyte Glycoprotein for Experimental Autoimmune Encephalomyelitis Studies

Published on: October 27, 2016

Area of Science:

  • Neuroimmunology
  • Autoimmune Diseases
  • Molecular Immunology

Background:

  • Organ-specific autoimmune diseases necessitate precise identification of immunogenic epitopes.
  • Autoimmune diseases involve pathogenic T cells and autoantibodies recognizing specific molecular targets.
  • Multiple Sclerosis (MS) is a significant organ-specific autoimmune disease affecting the central nervous system.

Purpose of the Study:

  • To review studies identifying immunogenic peptides in Multiple Sclerosis (MS).
  • To analyze T cell reactivity differences between MS patients and healthy controls against these peptides.
  • To discuss the implications of identifying pathogenic MS epitopes for diagnostics and therapeutics.

Main Methods:

  • Literature review of studies on MS epitope identification.
  • Analysis of reported T cell reactivity data in MS patients versus controls.
  • Synthesis of current knowledge on MS immunogenic epitopes.

Main Results:

  • Few studies have reported significant differences in T cell reactivity to identified peptides between MS patients and controls.
  • The identified epitopes are recognized by pathogenic T cells and autoantibodies.

Conclusions:

  • Identifying specific MS epitopes is essential for developing targeted therapies.
  • Limited differences in T cell reactivity pose challenges for current diagnostic and therapeutic approaches.
  • Further research into pathogenic MS epitopes holds potential for future treatment strategies.